INS and metabolic dysfunction-associated steatotic liver disease: What is more, in recent years, some studies have found that thyroid hormone receptor agonists can inhibit hepatic triglyceride synthesis, increase hepatic total cholesterol clearance, reduce lipid deposition, and simultaneously partially enhance insulin sensitivity, promote glucose metabolism, improve inflammation, and have a certain therapeutic effect on NAFLD.